NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
YONSA (abiraterone acetate) by Fosun Pharma is abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/c17,20-lyase (cyp17). Approved for prostate cancer, metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer and 1 more indications. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YONSA (abiraterone acetate) is an oral androgen biosynthesis inhibitor approved in 2018 by Fosun Pharma for treating metastatic castration-resistant prostate cancer (CRPC) in combination with prednisone. The drug works by inhibiting the CYP17 enzyme, which is required for androgen production in testicular, adrenal, and prostatic tumor tissues, thereby reducing serum testosterone and other androgens. YONSA is a reformulated version of the earlier abiraterone acetate product ZYTIGA, positioned as an alternative option in the competitive CRPC treatment landscape dominated by newer androgen receptor inhibitors.
$0.0BPart D
8.0 years to LOEMechanism of Action
abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone…
Indications (4)
Worked on YONSA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.